Reviewer's report

**Title:** The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study

**Version:** 2 **Date:** 17 September 2011

**Reviewer:** Alessandra Lugaresi

**Reviewer's report:**

MS: 1565350716546367

The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study Karsten Beer, Martin Müller, Anna Marie Hew-Winzeler, Adriano Bont, Philippe Maire, Xiaojun You, Pamela Foulds, Jessica Mårland and Daniela Curtius

I suggest the following discretionary revisions for the sake of clarity, before accepting it for publication:

**ABSTRACT**

Conclusions: After 2 yrs of continuous treatment patients on IM IFN#-1a had fewer ISRs and were less likely to switch therapies due to this side effect than patients on other therapies. This study may have implications in selecting initial therapy or, for patients considering switching or discontinuing therapy because of ISRs, selecting an alternative option.

**TEXT**

**DISCUSSION** third para, highlighted lines: regimen, not regime

**Level of interest:** An article whose findings are important to those with closely related research interests

**Quality of written English:** Acceptable

**Statistical review:** Yes, and I have assessed the statistics in my report.

**Declaration of competing interests:**

I have in the past five years received reimbursement from Biogen Idec and Biogen Dompé, Bayer Schering, Merck Serono, Novartis, Sanofi Aventis and Teva, fees and funding from Biogen Dompé, Bayer Schering, Merck Serono, Novartis, Sanofi Aventis